|
|
 |
|
Total Number of Holdings (excluding cash): 30
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Health Care |
1,182,693 |
$121,367,955.66 |
4.33% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Health Care |
980,857 |
$112,043,295.11 |
3.99% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Health Care |
135,618 |
$109,586,124.90 |
3.91% |
| BeOne Medicines Ltd. (ADR) |
ONC |
07725L102 |
Health Care |
301,714 |
$108,315,326.00 |
3.86% |
| Natera, Inc. |
NTRA |
632307104 |
Health Care |
333,848 |
$106,280,510.80 |
3.79% |
| NeoGenomics, Inc. |
NEO |
64049M209 |
Health Care |
6,387,041 |
$106,216,491.83 |
3.79% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Health Care |
1,524,374 |
$104,998,881.12 |
3.74% |
| Amgen Inc. |
AMGN |
031162100 |
Health Care |
248,000 |
$103,465,600.00 |
3.69% |
| Repligen Corporation |
RGEN |
759916109 |
Health Care |
624,802 |
$101,948,942.34 |
3.63% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Health Care |
185,664 |
$97,271,226.24 |
3.47% |
| ADMA Biologics, Inc. |
ADMA |
000899104 |
Health Care |
9,925,235 |
$96,771,041.25 |
3.45% |
| Genmab A/S (ADR) |
GMAB |
372303206 |
Health Care |
3,107,623 |
$95,932,322.01 |
3.42% |
| Incyte Corporation |
INCY |
45337C102 |
Health Care |
772,184 |
$93,858,965.20 |
3.35% |
| Biogen Inc. |
BIIB |
09062X103 |
Health Care |
452,532 |
$93,732,953.16 |
3.34% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Health Care |
694,145 |
$92,362,933.70 |
3.29% |
| BioNTech SE (ADR) |
BNTX |
09075V102 |
Health Care |
985,041 |
$91,411,804.80 |
3.26% |
| Bio-Techne Corporation |
TECH |
09073M104 |
Health Care |
1,263,968 |
$91,157,372.16 |
3.25% |
| Illumina, Inc. |
ILMN |
452327109 |
Health Care |
473,820 |
$90,873,937.80 |
3.24% |
| argenx SE (ADR) |
ARGX |
04016X101 |
Health Care |
102,690 |
$88,940,835.90 |
3.17% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Health Care |
164,739 |
$87,255,658.74 |
3.11% |
| Madrigal Pharmaceuticals, Inc. |
MDGL |
558868105 |
Health Care |
167,915 |
$86,533,316.10 |
3.08% |
| Alkermes Plc |
ALKS |
G01767105 |
Health Care |
1,735,099 |
$85,713,890.60 |
3.06% |
| Axsome Therapeutics, Inc. |
AXSM |
05464T104 |
Health Care |
385,465 |
$85,145,363.85 |
3.04% |
| Bruker Corporation |
BRKR |
116794108 |
Health Care |
1,500,516 |
$84,509,061.12 |
3.01% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Health Care |
1,595,059 |
$84,474,324.64 |
3.01% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Health Care |
508,842 |
$83,918,222.64 |
2.99% |
| Sarepta Therapeutics, Inc. |
SRPT |
803607100 |
Health Care |
4,755,729 |
$81,703,424.22 |
2.91% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Health Care |
1,577,748 |
$77,562,091.68 |
2.76% |
| Veracyte, Inc. |
VCYT |
92337F107 |
Health Care |
1,581,903 |
$73,194,651.81 |
2.61% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Health Care |
301,651 |
$65,452,233.98 |
2.33% |
| US Dollar |
$USD |
|
Other |
3,334,761 |
$3,334,761.38 |
0.12% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|